Skip to content

Merck & Co. MRK Price / earnings

Price / earnings at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
17×-6.2×
Pfizer logo
PfizerPFE
14.7×
Johnson & Johnson logo
Johnson & JohnsonJNJ
28×+9.7×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
18.5×+3.1×
United Therapeutics logo
United TherapeuticsUTHR
20.2×+8.8×
Amgen logo
AmgenAMGN
24.3×-3.9×

Other financials

Income statement

See full
Revenue$16.3B+4.9%
Gross profit$12.1B-0.2%
Net income-$4.2B-183%
EPS (diluted)-$1.72-186%

Balance sheet

See full
Cash & equivalents$5.4B-38.2%
Total debt$49.1B+35.8%
Total equity$45.9B-5.1%
Total assets$128.69B+11.8%

Cash flow

See full
Operating cash flow$3.9B+56.7%
CapEx$991.0M-25.4%
Free cash flow$2.9B+150%

Valuation

See full
Market cap$285.12B+31.2%
Enterprise value$328.82B+34.2%
P/S4.3×+0.9×

Profitability

See full
Gross margin73.9%-2.5pp
Net margin13.6%-13.7pp

Returns & leverage

See full
Return on equity19%-20.3pp
Debt / equity1.1×+0.3×
Current ratio1.3×-0.1×

Where this comes from

Calculated from Merck & Co.’s reported figures.

Based on the most recent quarter.

The official record: Merck & Co.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Merck & Co.'s price / earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Merck & Co.'s price / earnings?
Merck & Co. (MRK) reported price / earnings of 33.3× in Q1 2026.
How has Merck & Co.'s price / earnings changed year-over-year?
Merck & Co.'s price / earnings increased by 155.9% year-over-year, from 13× to 33.3×.
What does price / earnings mean?
How many dollars investors pay for each dollar of the company's annual profit.
How do you interpret price / earnings?
Lower can mean cheaper — or that the market expects earnings to fall. High multiples embed growth expectations. Meaningless when earnings are negative, so it is suppressed there.
How does price / earnings compare across companies?
Compare against the company's own history and sector peers, not across sectors with different growth and risk profiles.